{"id":6819,"date":"2024-12-06T11:59:57","date_gmt":"2024-12-06T10:59:57","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress&p=6819"},"modified":"2025-12-18T20:01:34","modified_gmt":"2025-12-18T19:01:34","slug":"ash","status":"publish","type":"congress","link":"https:\/\/beonemedaffairs.com\/us\/congress\/6819\/ash\/","title":{"rendered":"ASH"},"content":{"rendered":"","protected":false},"template":"","meta":{"_acf_changed":false,"editor_notices":[]},"specialisation":[],"class_list":["post-6819","congress","type-congress","status-publish","hentry","association-ash"],"acf":{"show_in_cards":true,"show_in_filter":true,"visible_for_guests":false,"show_popup":true,"acronym":"ASH","title":"American Society of Hematology","sub-heading-override":"ASH Annual Meeting and Exposition","congress_type":"","start_date":"2025-12-06T00:00:00+00:00","end_date":"2025-12-09T00:00:00+00:00","location":"Orlando, FL","extra_flag":"","deactivated":false,"alternate_button_text":"","tag":false,"content_block":null,"ics_file":null,"summary":"American Society of Hematology","related":"","field_page_schema_override":[{"field_page_schema_override_type":"EducationEvent","field_page_schema_override_data":"{\r\n  \"@type\": \"EducationEvent\",\r\n  \"name\": \"ASH Annual Meeting and Exposition\",\r\n  \"alternateName\": [\"67th ASH Annual Meeting and Exposition\", \"ASH Congress 2025\", \"2025 ASH\u00ae Annual Meeting\"],\r\n  \"description\": \"Explore BeOne Medicines' data presentations and other congress resources from the 2025 American Society of Hematology (ASH) Annual Meeting\",\r\n  \"startDate\": \"2025-12-06\",\r\n  \"endDate\": \"2025-12-09\",\r\n  \"eventStatus\": \"https:\/\/schema.org\/EventScheduled\",\r\n  \"eventAttendanceMode\": \"https:\/\/schema.org\/MixedEventAttendanceMode\",\r\n  \"location\": {\r\n    \"@type\": \"Place\",\r\n     \"name\": \"Orange County Convention Center\",\r\n       \"address\": {\r\n      \"@type\": \"PostalAddress\",\r\n       \"addressLocality\": \"Orlando\",\r\n      \"addressRegion\": \"Florida\",\r\n      \"addressCountry\": \"US\"\r\n    }\r\n  },\r\n  \"organizer\": {\r\n    \"@type\": \"Organization\",\r\n    \"@id\": \"beonemedicines.com\/#beone-org\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedicines.com\/\",\r\n    \"logo\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  },\r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2024\/12\/sandiego-aspect-ratio-1920-400-1.jpg\", \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/\",\r\n  \"inLanguage\": \"en-US\",\r\n  \"audience\": [\r\n  {\"@type\": \"MedicalAudience\", \"audienceType\": \"Oncology Researchers\"},\r\n  {\"@type\": \"MedicalAudience\", \"audienceType\": \"Hematology Researchers\"},\r\n  {\"@type\": \"MedicalAudience\", \"audienceType\": \"Healthcare Professionals\"} \r\n],\r\n \"performer\": [\r\n    { \"@type\": \"Person\", \"name\": \"Constantine S. Tam, MBBS (Hons), MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Mazyar Shadman, MD, MPH\"},\r\n    { \"@type\": \"Person\", \"name\": \"Inhye E. Ahn, MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Pier Luigi Zinzani, MD, PhD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Jennifer R. Brown, MD, PhD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Gurjyot Doshi, MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Aryan Ayati, MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Ryan Jacobs, MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Michael Wang, MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Meghan C. Thompson, MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Hang Quach, MBBS (Hons), MD, FRACP, FRCPA\"},\r\n    { \"@type\": \"Person\", \"name\": \"Marc S. Hoffmann, MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Othman Al-Sawaf, MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Li Wang, PhD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Chan Y. Cheah, MBBS (Hons), FRACP, FRCPA, Doctor of Medical Science\"},\r\n    { \"@type\": \"Person\", \"name\": \"Mengyang Di, PhD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Javier Pinilla-Ibarz, MD, PhD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Brian Koffman, MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Toby A. Eyre, MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Jacqueline C. Barrientos, MD, MS\"},\r\n    { \"@type\": \"Person\", \"name\": \"Sikander Ailawadhi, MD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Fei Li, PhD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Loic Ysebaert, MD, PhD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Jing-Zhou Hou, MD, PhD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Romain Gui\u00e8ze, MD, PhD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Shuhua Yi, PhD\"},\r\n    { \"@type\": \"Person\", \"name\": \"Paul Hampel, MD\"}\r\n  ]\r\n}"},{"field_page_schema_override_type":"ItemList","field_page_schema_override_data":"{\r\n  \"@type\": \"ItemList\",\r\n  \"name\": \"ASH 2025 Congress Resources\",\r\n  \"itemListElement\": [\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 1,\r\n      \"name\": \"Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (TN SLL\/CLL) with continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Constantine S. Tam, MBBS (Hons), MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-sequoia-6-year-long-term-data-of-zanubrutinib-vs-bendamustine-plus-rituximab-in-tn-cll-sll\/\",\r\n      \"datePublished\": \"2025-12-06\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295850\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 2,\r\n      \"name\": \"Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), including patients with del(17p) and\/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3 year results from SEQUOIA arm D\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Mazyar Shadman, MD, MPH\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/sequoia-arm-d-3-year-results-of-zanubrutinib-plus-venetoclax-for-tn-cll-sll-with-del17p-and-or-tp53-and-uighv\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295739\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 3,\r\n      \"name\": \"Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R\/R CLL\/SLL): Up to 6 years of follow-up with the long-term extension (LTE1)\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Constantine S. Tam, MBBS (Hons), MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-alpine-lte1-6-year-long-term-data-of-zanubrutinib-in-rr-cll-sll\/\",\r\n      \"datePublished\": \"2025-12-06\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/299044\", \r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 4,\r\n      \"name\": \"Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Inhye E. Ahn, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/prognostic-models-in-patients-treated-with-zanubrutinib-in-rr-cll-post-hoc-analysis\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/300997\", \r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 5,\r\n      \"name\": \"Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed\/refractory follicular lymphoma\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Pier Luigi Zinzani, MD, PhD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-2-rosewood-final-analysis-zanubrutinib-obinutuzumab-in-rr-follicular-lymphoma\/\",\r\n      \"datePublished\": \"2025-12-06\",\r\n      \"genre\": \"Oral Presentation\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295816\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 6,\r\n      \"name\": \"Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): Results from the ALPINE trial\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Jennifer R. Brown, MD, PhD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/symptom-based-progression-free-survival-in-cll-sll\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Oral Presentation\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/297085\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 7,\r\n      \"name\": \"Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Mazyar Shadman, MD, MPH\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/long-term-zanubrutinib-data-in-acalabrutinib-intolerant-b-cell-malignancies\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/289044\", \r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 8,\r\n      \"name\": \"Number needed to treat to avoid progression or death: Zanubrutinib vs other covalent Bruton tyrosine kinase inhibitors in relapsed\/refractory chronic lymphocytic leukemia\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Mazyar Shadman, MD, MPH\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/nnt-analysis-of-zanubrutinib-vs-other-covalent-btki-in-high-risk-rr-cll\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/302934\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 9,\r\n      \"name\": \"Outcomes during BTKi treatment for chronic lymphocytic leukemia: Insights from remote therapeutic monitoring\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Gurjyot Doshi, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/canopy-epro-based-rtm-outcomes-during-btki-treatment-in-cll\/\",\r\n      \"datePublished\": \"2025-12-06\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/302203\", \r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 10,\r\n      \"name\": \"Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Aryan Ayati, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/treatment-patterns-and-outcomes-of-second-gen-btk-inhibitors-in-cll\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/300354\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 11,\r\n      \"name\": \"Incidence of cardiac-related deaths among patients aged \u226565 years with B-cell malignancies treated with ibrutinib\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Ryan Jacobs, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/incidence-of-cardiac-related-deaths-65-years-and-older-with-b-cell-malignancies-treated-with-ibrutinib\/\",\r\n      \"datePublished\": \"2025-12-06\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_ABSTRACT_incidence-of-cardiac-related-deaths-65-years-and-older-with-b-cell-malignancies-treated-with-ibrutinib.pdf\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 12,\r\n      \"name\": \"Sonrotoclax (BGB-11417) monotherapy in patients with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) previously treated with a Bruton tyrosine kinase (BTK) inhibitor: Early results from a phase 1\/2 study\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Michael Wang, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-sonrotoclax-bgb-11417-monotherapy-in-previously-treated-btk-inhibitor-rr-mcl-patients\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Oral Presentation\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296316\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 13,\r\n      \"name\": \"Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1\/1b study\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Constantine S. Tam, MBBS (Hons), MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-1b-bgb-11417-101-study-of-sonrotoclax-plus-zanubrutinib-in-tn-cll-sll_umrd\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/293262\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 14,\r\n      \"name\": \"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Meghan C. Thompson, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-study-results-of-btk-degrader-bgb-16673-in-rr-rt\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295814\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 15,\r\n      \"name\": \"Initial phase 1b\/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed\/refractory multiple myeloma\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Hang Quach, MBBS (Hons), MD, FRACP, FRCPA\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/initial-phase-1b-2-sonrotoclax-with-carfilzomib-and-dexamethasone-in-rr-mm-t1114-positive\/\",\r\n      \"datePublished\": \"2025-12-06\",\r\n      \"genre\": \"Oral Presentation\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295923\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 16,\r\n      \"name\": \"MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1\/1b study, BGB-11417-101\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Marc S. Hoffmann, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-1b-initial-results-mrd-guided-therapy-sonrotoclax-plus-obinutuzumab-in-tn-cll\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Oral Presentation\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296134\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 17,\r\n      \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) from the ongoing phase 1 CaDAnCe-101 study\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Inhye E. Ahn, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-btk-degrader-bgb-16673-in-rr-cll-sll\/\",\r\n      \"datePublished\": \"2025-12-06\",\r\n      \"genre\": \"Oral Presentation\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296994\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 18,\r\n      \"name\": \"A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL-RR1\/CELESTIAL-RRCLL)\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Othman Al-Sawaf, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-study-of-sonrotoclax-plus-anti-cd20-vs-venetoclax-plus-rituximab-in-patients-with-rr-cll-sll\/\",\r\n      \"datePublished\": \"2025-12-06\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296353\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 19,\r\n      \"name\": \"BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Li Wang, PhD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-2-bgb-3111-218-zanubrutinib-in-cd79b-mutated-rr-dlbcl\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/293291\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 20,\r\n      \"name\": \"CaDAnCe-104, an ongoing, open-label, phase 1b\/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed\/refractory B-cell malignancies\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Chan Y. Cheah, MBBS (Hons), FRACP, FRCPA, Doctor of Medical Science\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/cadance-104-ongoing-phase-1b-2-btk-degrader-in-combination-with-other-agents-in-rr-b-cell-malignancies\/\",\r\n      \"datePublished\": \"2025-12-06\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296326\", \r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 21,\r\n      \"name\": \"CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Meghan C. Thompson, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-cadance-304-study-of-btk-degrader-bgb-16673-vs-pirtobrutinib-in-rr-cll-sll\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295784\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 22,\r\n      \"name\": \"Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL\/SLL\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Mengyang Di, PhD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/real-world-treatment-patterns-over-time-by-patients-cll-sll\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Poster\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296694\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 23,\r\n      \"name\": \"Chemo \u00b1 immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns and age disparities in the United States\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Javier Pinilla-Ibarz, MD, PhD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/real-world-cll-treatment-patterns-and-age-disparities-in-us\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/301117\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 24,\r\n      \"name\": \"Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Brian Koffman, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/genetic-marker-testing-impact-on-cll-treatment-selection-and-outcomes\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295705\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 25,\r\n      \"name\": \"Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Toby A. Eyre, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/indirect-comparison-of-efficacy-of-zanubrutinib-vs-ibrutinib-in-rr-mcl\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295938\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 26,\r\n      \"name\": \"Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Jacqueline C. Barrientos, MD, MS\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/real-world-mediators-of-racial-inequities-in-novel-cll-therapy-access-in-us\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295748\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 27,\r\n      \"name\": \"Patient preferences and factors affecting patient treatment decisions for chronic lymphocytic leukemia (CLL) in Japan\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Sikander Ailawadhi, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/patient-preferences-and-factors-affecting-patient-treatment-decisions-for-cll-in-japan\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295845\", \r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 28,\r\n      \"name\": \"Preliminary results from a phase 1\/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Fei Li, PhD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/preliminary-phase-1-1b-first-in-human-study-of-bgb-21447-in-nhl-patients\/\",\r\n      \"datePublished\": \"2025-12-06\",\r\n      \"genre\": \"Poster\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295882\", \r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 29,\r\n      \"name\": \"Progression-free survival (PFS) in patients with low health-related quality of life (HRQoL) treated with zanubrutinib versus ibrutinib monotherapy: Post hoc analysis of the ALPINE trial\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Loic Ysebaert, MD, PhD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/progression-free-survival-in-patients-with-low-hrqol-treated-with-zanubrutinib-vs-ibrutinib-in-rr-cll-sll\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Poster \",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/293266\", \r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 30,\r\n      \"name\": \"Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Jing-Zhou Hou, MD, PhD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/real-world-cll-treatment-patterns-with-venetoclax-combination-time-limited-therapy\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Poster\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/301089\", \r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 31,\r\n      \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Romain Gui\u00e8ze, MD, PhD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-indolent-nhl\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Poster\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296938\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 32,\r\n      \"name\": \"Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (TN CLL\/SLL): Initial results from an ongoing phase 1\/1b study, BGB-11417-101\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Jacob D. Soumerai, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-1b-initial-results-of-zanubrutinib-plus-obinutuzumab-plus-sonrotoclax-in-tn-cll-sll\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Poster\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/292758\", \r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 33,\r\n      \"name\": \"Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL)\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Shuhua Yi, PhD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/primary-analysis-phase-2-study-of-sonrotoclax-monotherapy-in-rr-cll-sll\/\",\r\n      \"datePublished\": \"2025-12-08\",\r\n      \"genre\": \"Poster\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/292530\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 34,\r\n      \"name\": \"Real-world treatment patterns and biomarker utilization among patients aged \u226565 years with CLL\/SLL from 2020 to 2024\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Paul Hampel, MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/real-world-treatment-patterns-and-biomarker-use-in-cll-sll-patients-aged-gte-65-years\/\",\r\n      \"datePublished\": \"2025-12-06\",\r\n      \"genre\": \"Poster\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295964\",\r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    },\r\n{\r\n      \"@type\": \"PresentationDigitalDocument\",\r\n      \"position\": 35,\r\n      \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study\",\r\n      \"author\": { \"@type\": \"Person\", \"name\": \"Constantine S. Tam, MBBS (Hons), MD\" },\r\n      \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-wm\/\",\r\n      \"datePublished\": \"2025-12-07\",\r\n      \"genre\": \"Poster\",\r\n      \"associatedMedia\": {\r\n        \"@type\": \"MediaObject\",\r\n        \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296731\", \r\n        \"encodingFormat\": \"application\/pdf\"\r\n      }\r\n    }\r\n]\r\n}"}],"field_show_asset_alt":true},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6819"}],"wp:term":[{"taxonomy":"specialisation","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/specialisation?post=6819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}